Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
ORGANIZATION
Industry Calls for More Tailored Govt Support on Drug Loss Product Development
Pharmaceutical industry officials in Japan are urging the government to go beyond its current support framework for so-called “drug loss” products and provide clearer regulatory guidance and stronger incentives particularly for firms accepting open calls for development sponsors. Speaking to…
To read the full story
Related Article
- MHLW Seeks Sponsors for 6 High-Need Unapproved, Off-Label Drugs
July 2, 2026
- MHLW Panel Deems 4 More “Drug Loss” Products as High-Need
May 27, 2026
- Japan Identifies 28 New “Drug Loss” Products from 2021-23 Approvals
April 7, 2026
- MHLW Seeks Sponsors to Develop 8 “Drug-Loss” Products
March 2, 2026
- MHLW Panel Deems 10 “Drug Loss” Products as High-Need, to Seek Development
February 9, 2026
- MHLW Council Determines 3 “Drug Loss” Products as High-Need, to Seek Development
December 16, 2025
- MHLW Council Clears Public Knowledge Filing for MabCampath in T-PLL
October 1, 2025
- J-ENTRY Consortium Steps Up to Develop Two “Drug Loss” Products
July 9, 2025
- MHLW Seeks Development Sponsors for 5 “Drug Loss” Products
May 21, 2025
- MHLW to Help Match Domestic Firms with Overseas Originators to Fight Drug Loss
May 12, 2025
- MHLW Council Deems 11 “Loss” Products as Medically Highly Necessary
May 12, 2025
- Japan to Buttress Regulatory Communication Efforts for Drug Originators Overseas
April 25, 2025
- Japan Picks 14 “Loss” Products as Drugs with Highest Priority for Development
April 2, 2025
- Japan Gets Down to the Business of Solving Drug Loss, New Scheme Begins with 78 Meds
November 26, 2024
- MHLW Lists Up 78 Drug-Loss Assets, Asks Makers to Report Any Hurdles in Development
October 28, 2024
- MHLW Proposes New Scheme for Development Requests to Fight Drug Loss
July 8, 2024
ORGANIZATION
- Pharma Urges Drug Security, Demands 8.5% Price Hike: LDP Hearing
October 30, 2026
- Pharma Labor Group Seeks Political Push for Price Hikes, Fair Cost Sharing
October 30, 2026
- UA Zensen Targets 6% Wage Hike Demand for 2027
October 28, 2026
- JaDHA Keen to Grab Chuikyo Seat to Speed Reimbursement for Digital Health
October 27, 2026
- FPMAJ Urges Member Groups to Share Government PHP Security Alert
October 26, 2026
The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…